The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Could BTKis play a role in DLBCL through rational combinations?
In this video, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, briefly discusses whether BTK inhibitors (BTKis) may still play a role in diffuse large B-cell lymphoma (DLBCL) through rational combinations, highlighting the promising data with acalabrutinib, lenalidomide, and rituximab in the upfront setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think rational combinations makes the most sense. You know, we are also moving away from chemo-based regimens. And I think here, you know, an approach that Dr Jason Westin, the Smart Start, the Smart Stop, wherein the targeting is done by targeted inhibitors and immunomodulators. So the data that we have with acalabrutinib-lenalidomide-rituximab in the upfront setting is very intriguing, seems very promising...
I think rational combinations makes the most sense. You know, we are also moving away from chemo-based regimens. And I think here, you know, an approach that Dr Jason Westin, the Smart Start, the Smart Stop, wherein the targeting is done by targeted inhibitors and immunomodulators. So the data that we have with acalabrutinib-lenalidomide-rituximab in the upfront setting is very intriguing, seems very promising. You don’t really lose a lot of bang for the buck if patients are not in remission and you add chemotherapy towards the back end. So I do believe that there is immense interest in developing BTK inhibitors in DLBCL. It’s all about precision medicine, targeting it for the right subtype at the right time.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
